文献速递其他结缔组织病

用于诊断系统性硬化症相关间质性肺病的复合血清生物标志物指数:一项多中心观察性队列研究

A Composite Serum Biomarker Index for the Diagnosis of Systemic Sclerosis-Associated Interstitial Lung Disease: A Multicenter, Observational Cohort Study.
PubMed 文献 · Arthritis Rheumatol · 2023-05-15

该多中心观察性队列研究分析了640名参与者的28种生物标志物,开发出由SP-D、Ca15-3和ICAM-1组成的复合血清生物标志物指数,该指数与系统性硬化症相关间质性肺病诊断强相关,且指数越高与基线疾病严重程度越重相关,可能改善该病的识别与风险分层。

要点

  • 复合指数由SP-D、Ca15-3和ICAM-1组成,与SSc-ILD诊断强相关。
  • 指数评分为3时,合并校正比值比为12.72(95%CI 4.59-35.21,P<0.001)。
  • 指数越高与基线疾病严重程度越重相关,FVC%pred和DLCO%pred均更低。

核心结论

  • 由SP-D、Ca15-3和ICAM-1组成的复合血清生物标志物指数可能改善系统性硬化症患者基线间质性肺病的识别和风险分层。

研究设计与样本

  • 多中心观察性队列研究,分析640名参与者的28种生物标志物。
  • 参与者包括259例SSc-ILD患者和179例无ILD的SSc患者(澳大利亚硬皮病队列研究)、172例IPF对照(澳大利亚IPF登记处)和30名健康对照。
  • 复合指数由多变量分析中与ILD相关的生物标志物在经验阈值下得出,并在推导队列和验证队列中评估其识别ILD(特别是SSc-ILD)的性能及其与肺功能、影像学疾病范围和患者健康相关生活质量的相关性。

主要发现

  • 复合生物标志物指数与SSc-ILD诊断强相关,独立于年龄、性别、吸烟史和肺功能;指数评分为3时,合并校正比值比为12.72(95%CI 4.59-35.21)(P<0.001)。
  • 复合指数增强了单个生物标志物识别SSc-ILD的性能。
  • 在SSc患者中,指数越高与基线疾病严重程度越重相关:相对于指数评分0,指数评分3时用力肺活量占预计值百分比的校正绝对变化为-17.84%,一氧化碳弥散量占预计值百分比的校正绝对变化为-20.16%;两者P<0.001。

关键数值与推荐

  • 复合指数评分为3时,合并校正比值比为12.72(95%CI 4.59-35.21)(P<0.001),与SSc-ILD诊断强相关。
  • 相对于指数评分0,指数评分3时FVC%pred校正绝对变化为-17.84%,DLCO%pred校正绝对变化为-20.16%,两者P<0.001。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In patients with systemic sclerosis (SSc), we investigated composite serum biomarker panels for the diagnosis and risk stratification of SSc-associated interstitial lung disease (SSc-ILD). METHODS: We analyzed 28 biomarkers in 640 participants: 259 patients with SSc-ILD and 179 SSc patients without ILD (Australian Scleroderma Cohort Study), 172 patients with idiopathic pulmonary fibrosis (IPF-controls) (Australian IPF Registry), and 30 healthy controls. A composite index was developed from biomarkers associated with ILD in multivariable analysis derived at empirical thresholds. We evaluated the performance of the index to identify ILD, and specifically SSc-ILD, and its association with lung function, disease extent on radiography, and patient health-related quality of life in derivation and validation cohorts. Biomarkers to distinguish SSc-ILD from IPF-controls were identified. RESULTS: A composite biomarker index, comprising surfactant protein D (SP-D), Ca15-3, and intercellular adhesion molecule 1 (ICAM-1), was strongly associated with SSc-ILD diagnosis, independent of age, sex, smoking history, and lung function (for biomarker index score 3, pooled adjusted odds ratio was 12.72 (95% confidence interval 4.59-35.21) (P < 0.001). The composite index strengthened the performance of individual biomarkers for SSc-ILD identification. In SSc patients, a higher index was associated with worse baseline disease severity (for biomarker index score 3 relative to biomarker index score 0, the adjusted absolute change in forced vital capacity percent predicted was -17.84% and the diffusing capacity for carbon monoxide percent predicted was -20.16%; both P < 0.001). CONCLUSION: A composite serum biomarker index, comprising SP-D, Ca15-3, and ICAM-1, may improve the identification and risk stratification of ILD in SSc patients at baseline.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Jee AS, Stewart I, Youssef P, et al. A Composite Serum Biomarker Index for the Diagnosis of Systemic Sclerosis-Associated Interstitial Lung Disease: A Multicenter, Observational Cohort Study. Arthritis Rheumatol. 2023. PMID: 36908055. doi:10.1002/art.42491

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。